Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AKT2000
- Development stage
- Preclinical
- Lead developer
- Akkadian Therapeutics
- Modality
- Small Molecules
01
Overview
AKT2000 is a drug candidate series being developed by Akkadian Therapeutics for the treatment of Postural Orthostatic Tachycardia Syndrome (POTS). POTS is a form of dysautonomia characterized by an excessive increase in heart rate upon standing, which can lead to symptoms such as lightheadedness, palpitations, and fatigue. The AKT2000 program is currently in the preclinical stage of development. While specific details regarding its molecular target and mechanism of action have not been publicly disclosed, Akkadian Therapeutics focuses on the discovery and development of small molecule therapeutics for conditions with significant unmet medical needs.
- Other names
- AKT2000 seriesAKT-2000 seriesAKT 2000 series
Beyond the preview
Go deeper on AKT2000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AKT2000.